Accessed February 2, 2016. Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors . Cancer Biol Med. 2015;12:201–8. Koehne G, Devlin S, Chung DJ, et al. WT1 heteroclitic epitope immunization following autologous stem cell transplantation in patients with high -risk multiple myeloma (MM). J Clin Oncol. 2017; 35(15_suppl): 8016 (also accessible at: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.8016). Koehne G, Devlin S, Korde N, et al. Clinical benefit after galinpepimut -S (GPS), a WT1 immunotherapeutic, correlates with antigen -specific immune responses in high-risk multiple myeloma: complete analysis of the Ph2 GPS maintenance study. 44 th Ann. Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 2018; Abstr. # O132; SELLAS Life Sciences Group Galinpepimut -S Protocol : SLS17 -201/ MK3475 -770 Protocol v1.1 (Amendment 1.0) 12 April 2019 Page 243 https://www.nature.com/articles/s41409-018-0318-y (also accessible at: https://www.slideshare.net/njsarlis/ebmt-2018-gps-in-mm-koehne-et-alwith -suppl- slidesfinalfinal1112mar2018copy) Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol.